|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
An H, Tao N, Li J, Guan Y, Wang W, Wang Y
and Wang F: detection of prostate cancer metastasis by whole body
magnetic resonance imaging combined with bone scintigraphy and PSA
Levels. Cell Physiol Biochem. 40:1052–1062. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen SL, Wang SC, Ho CJ, Kao YL, Hsieh TY,
Chen WJ, Wu PR, Ko JL, Lee H and Sung WW: Prostate cancer
mortality-to-incidence ratios are associated with cancer care
disparities in 35 countries. Sci Rep. 7:4000032017.
|
|
4
|
Pan XW, Gan SS, Ye JQ, Fan YH, Hong Υ, Chu
CM, Gao Y, Li L, Liu X, Chen L, et al: SMC1A promotes growth and
migration of prostate cancer in vitro and in vivo. Int J Oncol.
49:1963–1972. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ost P, Bossi A, Decaestecker K, De
Meerleer G, Giannarini G, Karnes RJ, Roach M III and Briganti A:
Metastasis-directed therapy of regional and distant recurrences
after curative treatment of prostate cancer: A systematic review of
the literature. Eur Urol. 67:852–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pettersson A, Robinson D, Garmo H,
Holmberg L and Stattin P: Age at diagnosis and prostate cancer
treatment and prognosis: A population-based cohort study. Ann
Oncol. 29:377–385. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jemal A, Fedewa SA, Ma J, Siegel R, Lin
CC, Brawley O and Ward EM: prostate cancer incidence and PSA
testing patterns in relation to USPSTF screening recommendations.
JAMA. 314:2054–2061. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Chen Z, Wang T, Liu L, Zhao L, Guo
G and Wang D: influence of four radiotracers in PET/CT on
diagnostic accuracy for prostate cancer: A Bivariate Random-Effects
Meta-Analysis. Cell Physiol Biochem. 39:467–480. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barrington WE, Schenk JM, Etzioni R,
Arnold KB, Neuhouser ML, Thompson IM Jr, Lucia MS and Kristal AR:
Difference in association of obesity with prostate cancer risk
between US African American and Non-Hispanic White Men in the
Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA
Oncol. 1:342–349. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vidal AC, Howard LE, Sun SX, Cooperberg
MR, Kane CJ, Aronson WJ, Terris MK, Amling CL and Freedland SJ:
Obesity and prostate cancer-specific mortality after radical
prostatectomy: Results from the Shared Equal Access Regional Cancer
Hospital (SEARCH) database. Prostate Cancer Prostatic Dis.
20:72–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gambari R, Brognara E, Spandidos DA and
Fabbri E: Targeting oncomiRNAs and mimicking tumor suppressor
miRNAs: Νew trends in the development of miRNA therapeutic
strategies in oncology (Review). Int J Oncol. 49:1–32. 2016.
View Article : Google Scholar
|
|
12
|
Gao Y, Feng B, Han S, Lu L, Chen Y, Chu X,
Wang R and Chen L: MicroRNA-129 in human cancers: From
tumorigenesis to clinical treatment. Cell Physiol Biochem.
39:2186–2202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paul P, Chakraborty A, Sarkar D, Langthasa
M, Rahman M, Bari M, Singha RS, Malakar AK and Chakraborty S:
Interplay between miRNAs and Human Diseases: A Review. J Cell
Physiol. 233:2007–2018. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie T, Huang M, Wang Y, Wang L, Chen C and
Chu X: MicroRNAs as regulators, biomarkers and therapeutic targets
in the drug resistance of colorectal cancer. Cell Physiol Biochem.
40:62–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Tang W, Li R, He R, Gan T, Luo Y,
Chen G and Rong M: Downregulation of microRNA-132 indicates
progression in hepatocellular carcinoma. Exp Ther Med.
12:2095–2101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang WT, Wang HL, Yang H, Ren FH, Luo YH,
Huang CQ, Liang YY, Liang HW, Chen G and Dang YW: Lower expressed
miR-198 and its potential targets in hepatocellular carcinoma: A
clinicopathological and in silico study. OncoTargets Ther.
9:5163–5180. 2016. View Article : Google Scholar
|
|
17
|
Pang C, Liu M, Fang W, Guo J, Zhang Z, Wu
P, Zhang Y and Wang J: MiR-139-5p is increased in the peripheral
blood of patients with prostate cancer. Cell Physiol Biochem.
39:1111–1117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
van Beijnum JR, Giovannetti E, Poel D,
Nowak-Sliwinska P and Griffioen AW: miRNAs: Micro-managers of
anticancer combination therapies. Angiogenesis. 20:269–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu C, Zhuang Y, Jiang S, Liu S, Zhou J, Wu
J, Teng Y, Xia B, Wang R and Zou X: Interaction between
Wnt/β-catenin pathway and microRNAs regulates
epithelial-mesenchymal transition in gastric cancer (Review). Int J
Oncol. 48:2236–2246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang X, Pang YY, He RQ, Lin P, Cen JM,
Yang H, Ma J and Chen G: Diagnostic value of strand-specific
miRNA-101-3p and miRNA-101-5p for hepatocellular carcinoma and a
bioinformatic analysis of their possible mechanism of action. FEBS
Open Bio. 8:64–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng Q, Huang X and Urology DO: Expression
of miRNA-32, −196a,-218,-128 and let7i in serum of patients with
prostate cancer and its clinical significance. Guangdong Yixue.
2016.
|
|
22
|
Pan Y, Gan Q, Jun LU, Huang T and Mang KE:
Serological determination and its clinical significance of
miRNA-129 and miRNA-21 in prostate cancer patients. Chinese Journal
of Health Laboratory Technology. 2016.
|
|
23
|
Yao CH, Yuan XC, Liu C and Deng JP:
Expression and diagnostic value of miRNA-15a in prostate cancer.
Chin J Immunol. 2016.
|
|
24
|
Lu S, Wang MS, Chen PJ, Ren Q and Bai P:
miRNA-186 inhibits prostate cancer cell proliferation and tumor
growth by targeting YY1 and CDK6. Exp Ther Med. 13:3309–3314. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tian XM, Luo YZ, He P, Li J, Ma ZW and An
Y: Inhibition of invasion and migration of prostate cancer cells by
miRNA-509-5p via targeting MDM2. Genet Mol Res. 16:doi:
10.4238/gmr16019195.
|
|
26
|
Mavridis K, Stravodimos K and Scorilas A:
Downregulation and prognostic performance of microRNA 224
expression in prostate cancer. Clin Chem. 59:261–269. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu H, He HC, Han ZD, Wan YP, Luo HW, Huang
YQ, Cai C, Liang YX, Dai QS, Jiang FN, et al: MicroRNA-224 and its
target CAMKK2 synergistically influence tumor progression and
patient prognosis in prostate cancer. Tumour Biol. 36:1983–1991.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kristensen H, Haldrup C, Strand S,
Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov
C, Goering W, et al: Hypermethylation of the GABRE~miR-452~miR-224
promoter in prostate cancer predicts biochemical recurrence after
radical prostatectomy. Clin Cancer Res. 20:2169–2181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen M, Wang J, Luo Y, Huang K, Shi X, Liu
Y, Li J, Lai Z, Xue S, Gao H, et al: Identify Down syndrome
transcriptome associations using integrative analysis of microarray
database and correlation-interaction network. Hum Genomics.
12:22018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He X, Zhang C, Shi C and Lu Q:
Meta-analysis of mRNA expression profiles to identify
differentially expressed genes in lung adenocarcinoma tissue from
smokers and non-smokers. Oncol Rep. 39:929–938. 2018.PubMed/NCBI
|
|
32
|
Li F, Shi W, Wan Y, Wang Q, Feng W, Yan X,
Wang J, Chai L, Zhang Q and Li M: Prediction of target genes for
miR-140-5p in pulmonary arterial hypertension using bioinformatics
methods. FEBS Open Bio. 7:1880–1890. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang L, Zeng JH, Wang JY, He RQ, Ma J,
Chen G, Cai XY and Hu XH: Down-regulation of miR-26a-5p in
hepatocellular carcinoma: A qRT-PCR and bioinformatics study.
Pathol Res Pract. 213:1494–1509. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mi B, Liu G, Zhou W, Lv H, Liu Y and Liu
J: Identification of genes and pathways in the synovia of women
with osteoarthritis by bioinformatics analysis. Mol Med Rep.
17:4467–4473. 2018.PubMed/NCBI
|
|
35
|
Wang L, Peng Z, Wang K, Qi Y, Yang Y,
Zhang Y, An X, Luo S and Zheng J: NDUFA4L2 is associated with clear
cell renal cell carcinoma malignancy and is regulated by ELK1.
PeerJ. 5:e40652017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei D: A multigene support vector machine
predictor for metastasis of cutaneous melanoma. Mol Med Rep.
17:2907–2914. 2018.PubMed/NCBI
|
|
37
|
Zhang H, Liu J, Fu X and Yang A:
Identification of key genes and pathways in tongue squamous cell
carcinoma using bioinformatics analysis. Med Sci Monit.
23:5924–5932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang L, Huang LS, Chen G and Feng ZB:
Potential targets and clinical value of miR-224-5p in cancers of
the digestive tract. Cell Physiol Biochem. 44:682–700. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou F, Li S, Meng HM, Qi LQ and Gu L:
MicroRNA and histopathological characterization of pure mucinous
breast carcinoma. Cancer Biol Med. 10:22–27. 2013.PubMed/NCBI
|
|
40
|
Zheng X, Tang H, Zhao X, Sun Y, Jiang Y
and Liu Y: Long non-coding RNA FTH1P3 facilitates uveal melanoma
cell growth and invasion through miR-224-5p. PLoS One.
12:e01847462017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC,
Ling XH, Fu X, Dai QS, Cai C, Chen JH, et al: MicroRNA-224 inhibits
progression of human prostate cancer by downregulating TRIB1. Int J
Cancer. 135:541–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wan Y, Zeng ZC, Xi M, Wan S, Hua W, Liu
YL, Zhou YL, Luo HW, Jiang FN and Zhong WD: Dysregulated
microRNA-224/apelin axis associated with aggressive progression and
poor prognosis in patients with prostate cancer. Hum Pathol.
46:295–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cao J, Lu XX, Li Y, Zhu LQ, Yang C, Ou C
and Tang YP: Applying gene set enrichment analysis and
meta-analysis to screen key genes controlling the development and
progression of hepatic carcinoma. World Chin J Digestology.
20:7542012.(In Chinese). View Article : Google Scholar
|
|
44
|
Li Z, Li BQ, Jiang M, Chen L, Zhang J, Liu
L and Huang T: Prediction and analysis of retinoblastoma related
genes through gene ontology and KEGG. Biomed Res Int.
2013:3040292013.PubMed/NCBI
|
|
45
|
Itkonen HM, Engedal N, Babaie E, Luhr M,
Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T and Mills
IG: UAP1 is overexpressed in prostate cancer and is protective
against inhibitors of N-linked glycosylation. Oncogene.
34:3744–3750. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kudryavtseva AV, Nyushko KM, Zaretsky AR,
et al: Expression of HK2 gene is deregulated in Prostate cancer.
Asian J Pharm. 11:S158–S161. 2017.
|
|
47
|
Tao T, Chen M, Jiang R, Guan H, Huang Y,
Su H, Hu Q, Han X and Xiao J: Involvement of EZH2 in aerobic
glycolysis of prostate cancer through miR-181b/HK2 axis. Oncol Rep.
37:1430–1436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tao T, Xiang P and Huang T: Expression of
HK2 in prostate cancer and its effect on malignant phenotype of
prostate cancer cells. Chinese Journal of Clinical &
Experimental Pathology. 2017.
|
|
49
|
Li FF, Yan P, Zhao ZX, Liu Z, Song DW,
Zhao XW, Wang XS, Wang GY and Liu SL: Polymorphisms in the CHIT1
gene: Associations with colorectal cancer. Oncotarget.
7:39572–39581. 2016.PubMed/NCBI
|
|
50
|
Schaefer-Klein JL, Murphy SJ, Johnson SH,
Vasmatzis G and Kovtun IV: Topoisomerase 2 alpha cooperates with
androgen receptor to contribute to prostate cancer progression.
PLoS One. 10:e01423272015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shah S, Carriveau WJ, Li J, Campbell SL,
Kopinski PK, Lim HW, Daurio N, Trefely S, Won KJ, Wallace DC, et
al: Targeting ACLY sensitizes castration-resistant prostate cancer
cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback
mechanism. Oncotarget. 7:43713–43730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xin M, Qiao Z, Li J, Liu J, Song S, Zhao
X, Miao P, Tang T, Wang L, Liu W, et al: miR-22 inhibits tumor
growth and metastasis by targeting ATP citrate lyase: Evidence in
osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Oncotarget. 7:44252–44265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Afrasiabi A, Fiuji F, Mirhafez R and Avan
A: RRM2 (ribonucleotide reductase M2). Atlas Genet Cytogenet Oncol
Haematol. 19:p32–37. 2015.
|
|
54
|
Huang Y, Liu X, Wang YH, Yeh SD, Chen CL,
Nelson RA, Chu P, Wilson T and Yen Y: The prognostic value of
ribonucleotide reductase small subunit M2 in predicting recurrence
for prostate cancers. Urol Oncol. 32:51.e9–51.e19. 2014. View Article : Google Scholar
|
